French biotech company wants to challenge Novo and Lilly: "They are not unreachable"
Changed dynamics in the insulin market mean Novo Nordisk and Eli Lilly are not as invincible as in the past, says a director from Adocia. The French biotech company aims to take on the giants - and also compete with Zealand Pharma in another segment of the diabetes market.
For a long time, Danish drug group Novo Nordisk and US-based Eli Lilly have had sort of a duopoly on the global mealtime insulin market. However, things might be about to change.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Novo CSO welcomes rival's success
For abonnenter
